KORU Medical Systems (KRMD) Projected to Post Earnings on Tuesday

Key Points

• KORU Medical Systems is expected to report Q3 2026 results after the market closes Tuesday, November 10. Analysts forecast a loss of $0.0168 per share on revenue of approximately $11.33 million.
• In the prior quarter, KORU earned $0.01 per share and generated $12.05 million in revenue, exceeding analyst expectations for both measures. Analysts project full-year EPS of negative $0.02 and next-year EPS of $0.05.
• KRMD shares recently traded near $3.12, well below their 12-month high of $6.61. Despite mixed analyst opinions, the stock has a consensus “Moderate Buy” rating and a $7.00 price target; an insider also recently purchased 32,000 shares.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) will likely be posting its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect KORU Medical Systems to announce earnings of ($0.0168) per share and revenue of $11.33 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The business had revenue of $12.05 million for the quarter, compared to analysts' expectations of $11.62 million. KORU Medical Systems had a negative return on equity of 10.63% and a negative net margin of 4.03%. On average, analysts expect KORU Medical Systems to post ($0.02) EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

KORU Medical Systems Price Performance

KRMD stock traded up $0.07 during trading hours on Tuesday, reaching $3.12. 25,702 shares of the stock were exchanged, compared to its average volume of 185,310. The company has a market cap of $143.30 million, a price-to-earnings ratio of -77.98 and a beta of 0.39. KORU Medical Systems has a 12 month low of $2.86 and a 12 month high of $6.61. The firm's 50-day moving average is $3.13 and its 200-day moving average is $4.02.

Analyst Upgrades and Downgrades

KRMD has been the subject of a number of recent research reports. Craig Hallum restated a "buy" rating and set a $6.00 price objective on shares of KORU Medical Systems in a research note on Thursday, August 6th. Wall Street Zen raised KORU Medical Systems from a "hold" rating to a "buy" rating in a research report on Saturday, September 26th. Weiss Ratings lowered KORU Medical Systems from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, September 29th. Finally, Zacks Research cut KORU Medical Systems from a "strong-buy" rating to a "hold" rating in a research report on Friday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Insider Activity at KORU Medical Systems

In other news, insider Adam Kalbermatten bought 32,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The shares were bought at an average cost of $3.16 per share, with a total value of $101,120.00. Following the acquisition, the insider owned 394,017 shares in the company, valued at $1,245,093.72. This trade represents a 8.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 18.50% of the stock is currently owned by company insiders.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company's products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems.

KORU's principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.